We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Curcumin Used to Treat Alzheimer’s Disease

By LabMedica International staff writers
Posted on 26 Jan 2015
Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. More...
Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease.

“Curcumin has demonstrated ability to enter the brain, bind and destroy the beta-amyloid plaques present in Alzheimer’s with reduced toxicity,” said Wellington Pham, PhD, assistant professor of radiology and radiological sciences and biomedical engineering at Vanderbilt University Medical Center (Nashville, TN, USA), and senior author of the study, published January 2015 in the Journal of Alzheimer’s Disease.

Accumulation and aggregation of protein fragments, known as beta-amyloid, has been show to drive the irreversible loss of neurons in Alzheimer’s disease. Developing small molecules to reduce this accumulation or promote its demolition is crucial, but the ability of these small molecules to cross the blood-brain barrier has been an inhibiting factor for drug delivery into the brain.

Dr. Pham and colleagues at Shiga University of Medical Science (Otsu, Japan), developed a new approach to deliver a molecule similar to curcumin more effectively to the brain. “One of the difficulties in the treatment of Alzheimer’s disease is how to deliver drugs across the blood brain barrier,” he said. “Our body has designed this barrier to protect the brain from any toxic molecules that can cross into the brain and harm neurons. “But it is also a natural barrier for molecules designed for disease-modifying therapy,” Dr. Pham said.

To work around the problems of giving the drug intravenously, the researchers decided to develop an atomizer to generate a curcumin aerosol. The Japanese researchers developed a molecule similar to curcumin, FMeC1, which was the one actually used in this study.

“The advantage of the FMeC1 is that it is a perfluoro compound, which can be tracked by the biodistribution in the brain noninvasively using magnetic resonance imaging. Curcumin is a very simple chemical structure, so it is not expensive to generate the analog,” Dr. Pham stated. “In this way the drug can be breathed in and delivered to the brain,” he said, noting that nebulizers are out in the market already, and are relatively inexpensive. “In this paper, we also showed that delivery to the cortex and hippocampal areas is more efficient using aerosolized curcumin than intravenous injection in a transgenic mouse model of Alzheimer’s disease,” Dr. Pham said.

Related Links:

Vanderbilt University Medical Center
Shiga University of Medical Science



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.